You are now
leaving Joenja-HCP.com

If you'd like to stay, you may click "Cancel"
Cancel
Continue leaving
X
  • Home
  • >
  • Example Blocks

[eyebrow]
Joenja® (leniolisib)

Subhead

Find out how Joenja gets to the source of APDS

[copy for about APDS]

→

Explore the results with Joenja in treating APDS

See results (ages 12+)

→

See results (ages 4-11)

→

Access & Support

Resources

→

Clinical trial results

Subhead goes here

Jump to content:

Anchor Link 1

Anchor Link 2

Anchor Link 3

Rhoncus tempor sit morbi magna porttitor fusce et.

Consectetur et diam vulputate sed. Gravida accumsan eu est eget vitae eget rhoncus gravida. Habitant eu amet eu hendrerit convallis.

Primary button

→

Purus leo donec

Et bibendum vel ac quisque. Nec et pellentesque tincidunt accumsan nisi. Lacinia id nullam nunc blandit cursus vel fringilla non neque. Morbi nunc nunc suspendisse ut. Pulvinar mi sit etiam lectus eu aliquam magna leo consectetur.

Consectetur viverra cras

Dui dui vitae aenean sociis mattis. Massa volutpat sollicitudin elit lacus nulla. Vestibulum suspendisse nullam egestas sollicitudin egestas ullamcorper.

Primary button

→

Helpful resources for patients taking Joenja

Resource 1

Vivamus tincidunt vitae viverra elit ipsum. Sit pulvinar quam amet viverra viverra.

Get reminder ringtone

Resource 2

Quis a adipiscing tortor erat. Et dictum in nisi quis.

Resource 3

Quam ut eu ut est gravida porttitor sapien donec. Amet ut etiam in lorem facilisis massa.

Dictumst morbi in proin

  • Pharetra gravida nisl tincidunt nec. Bibendum pulvinar amet elementum euismod facilisi gravida arcu urna in. Amet sed blandit odio amet quam in erat cursus.
  • Ultricies nibh cras at pharetra lectus vitae vitae id mattis. Suspendisse commodo mi eleifend enim in risus cras massa massa. Malesuada ut rhoncus eget consequat sed sed mattis.

Secondary button

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
  • Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
  • cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

*

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

†

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

‡

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

§

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

ACRONYM, definition of acronym; ACRONYM, definition of acronym.

Callout: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt 

Headline

body copy

Headline

body copy

Headline

body copy

Headline

body copy

Headline

body copy

Headline

body copy

See how Joenja works to manage APDS

→

Find a physician

near you

→

APDS, activated PI3Kδ syndrome.

Indications and Usage

JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Indications and Usage

JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Important Safety Information

Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA.

JOENJA may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose. Additionally, advise women not to breastfeed during treatment with JOENJA and for 1 week after the last dose.

Live, attenuated vaccinations may be less effective if administered during JOENJA treatment.

JOENJA may cause hypersensitivity reaction(s), including anaphylaxis. Advise patients to discontinue JOENJA and to seek immediate medical attention if they develop any signs and symptoms of serious allergic reactions.

Use of JOENJA in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.

Avoid co-administration of JOENJA with other medications known to be strong CYP3A4 inhibitors, strong or moderate CYP3A4 inducers, or BCRP, OATP1B1, and OATP1B3 substrates.

The most common adverse reactions (incidence >10%) were headache, sinusitis, atopic dermatitis, and weight gain.

Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/ microL and there were no reports of infection associated with neutropenia.

Before prescribing JOENJA, please read the full Prescribing Information.

What Is APDS?

How Joenja Works

Joenja Results

Clinical Trial Results 12+ Clinical Trial Results 4-11 Joenja Safety Profile

Dosing & Administration

Access & Resources

APDS Assist Resources

Request a Rep

Prescribing Information Contact Us Privacy Policy Terms of Use Cookie Policy

Joenja and logo are registered trademarks of Pharming Intellectual Property, B.V.

©2026 Pharming Healthcare, Inc. All rights reserved.
JOE-US-2023-0009v10 02/26

Privacy settings

Decide which cookies you want to allow.

You can change these settings at any time. However, this can result in some functions no longer being available. For information on deleting the cookies, please consult your browser’s help function.

Learn more about the cookies we use.

With the slider, you can enable or disable different types of cookies:

  • Block all
  • Essentials
  • Functionality
  • Analytics
  • Advertising

This website will:

This website won't:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Keep track of what you input in a shopping cart
  • Essential: Authenticate that you are logged into your user account
  • Essential: Remember language version you selected
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Tailor information and advertising to your interests based on e.g. the content you have visited before. (Currently we do not use targeting or targeting cookies.
  • Advertising: Gather personally identifiable information such as name and location
  • Remember your login details
  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Keep track of what you input in a shopping cart
  • Essential: Authenticate that you are logged into your user account
  • Essential: Remember language version you selected
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Tailor information and advertising to your interests based on e.g. the content you have visited before. (Currently we do not use targeting or targeting cookies.
  • Advertising: Gather personally identifiable information such as name and location
Save & Close